Opus Genetics Inc
IRD1.080USD
+0.010+0.93%
交易中 （美東）報價延遲15分鐘
49.12M總市值
虧損本益比TTM
關於 Opus Genetics Inc 公司
Opus Genetics, Inc.（前身爲 Ocuphire Pharma, Inc.）是一家臨牀階段的眼科生物製藥公司。該公司致力於開發治療遺傳性視網膜疾病 (IRD) 患者的療法以及治療其他視網膜和屈光疾病患者的療法。其產品線包括基於腺相關病毒 (AAV) 的基因療法，用於治療導致不同形式的視網膜萎縮症、萊伯先天性黑蒙 (LCA) 和視網膜色素變性的基因突變。其最先進的基因治療項目旨在治療編碼萊伯西林蛋白的 LCA5 基因突變，目前正在進行 I/II 期開放標籤劑量遞增試驗，並正在獲取早期數據。該管道還包括 0.75% 酚妥拉明眼液（一種非選擇性 α-1 和 α-2 腎上腺素能拮抗劑，用於縮小瞳孔）和 APX3330（一種新型 Ref-1 小分子抑制劑，用於減緩非增生性糖尿病視網膜病變的進展）。
公司簡介
公司代碼IRD
公司名稱Opus Genetics Inc
上市日期Nov 30, 2004
CEODr. George Magrath
員工數量18
證券類型Ordinary Share
年結日Nov 30
公司地址8 Davis Drive
城市DURHAM
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編27713
電話12486819815
網址https://opusgtx.com/
公司代碼IRD
上市日期Nov 30, 2004
CEODr. George Magrath
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
691.31K
+247.13%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
318.65K
+33.24%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
167.86K
+89.98%
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+29.21%
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Chief Operating Officer
54.50K
+2625.00%
Dr. Benjamin R. Yerxa, Ph.D.
Dr. Benjamin R. Yerxa, Ph.D.
President, Director
President, Director
10.00K
-97.08%
Ms. Amy Rabourn
Ms. Amy Rabourn
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer
--
--
Dr. Ash Jayagopal, Ph.D.
Dr. Ash Jayagopal, Ph.D.
Chief Scientific and Development Officer
Chief Scientific and Development Officer
--
--
Dr. James S. Manuso
Dr. James S. Manuso
Independent Director
Independent Director
--
--
Dr. Jean Bennett, M.D., Ph.D.
Dr. Jean Bennett, M.D., Ph.D.
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. George Magrath
Dr. George Magrath
Chief Executive Officer, Director
Chief Executive Officer, Director
691.31K
+247.13%
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
318.65K
+33.24%
Mr. Sean Ainsworth
Mr. Sean Ainsworth
Independent Director
Independent Director
167.86K
+89.98%
Mr. Bernhard Hoffmann
Mr. Bernhard Hoffmann
Senior Vice President - Corporate Development and Operations
Senior Vice President - Corporate Development and Operations
130.49K
+29.21%
Mr. Joseph K. (Joe) Schachle
Mr. Joseph K. (Joe) Schachle
Chief Operating Officer
Chief Operating Officer
54.50K
+2625.00%
Dr. Benjamin R. Yerxa, Ph.D.
Dr. Benjamin R. Yerxa, Ph.D.
President, Director
President, Director
10.00K
-97.08%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月23日 週五
更新時間: 5月23日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Foundation Fighting Blindness Inc
15.91%
Perceptive Advisors LLC
7.25%
Nantahala Capital Management, LLC
5.29%
Opaleye Management Inc.
1.97%
Bios Equity Partners, LP.
1.67%
Other
67.91%
持股股東
持股股東
佔比
Foundation Fighting Blindness Inc
15.91%
Perceptive Advisors LLC
7.25%
Nantahala Capital Management, LLC
5.29%
Opaleye Management Inc.
1.97%
Bios Equity Partners, LP.
1.67%
Other
67.91%
股東類型
持股股東
佔比
Corporation
15.91%
Hedge Fund
7.85%
Private Equity
7.25%
Individual Investor
5.48%
Investment Advisor
5.10%
Investment Advisor/Hedge Fund
1.71%
Venture Capital
1.67%
Research Firm
0.63%
Bank and Trust
0.07%
Other
54.33%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
128
27.25M
45.67%
+17.35M
2025Q1
138
20.65M
39.75%
+13.58M
2024Q4
131
8.86M
28.50%
+3.96M
2024Q3
122
4.55M
16.47%
-580.64K
2024Q2
124
4.74M
17.35%
-706.54K
2024Q1
127
5.24M
21.33%
-1.10M
2023Q4
122
5.21M
22.35%
-525.41K
2023Q3
117
4.91M
22.05%
-1.09M
2023Q2
119
4.95M
23.60%
-1.34M
2023Q1
103
4.98M
23.80%
-1.17M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Foundation Fighting Blindness Inc
9.49M
15.91%
+6.93M
+270.10%
Apr 30, 2025
Perceptive Advisors LLC
4.33M
7.25%
+4.33M
--
Mar 31, 2025
Nantahala Capital Management, LLC
3.16M
5.29%
+3.16M
--
Mar 31, 2025
Opaleye Management Inc.
1.18M
1.97%
+1.18M
--
Mar 31, 2025
Bios Equity Partners, LP.
995.25K
1.67%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
992.20K
1.66%
--
--
Mar 31, 2025
Gallagher (Cam S)
940.87K
1.58%
+79.50K
+9.23%
Apr 30, 2025
Mink Brook Asset Management LLC
810.08K
1.36%
+810.08K
--
Mar 31, 2025
Bleichroeder LP
736.84K
1.24%
+736.84K
--
Mar 31, 2025
Magrath (George)
691.31K
1.16%
+492.16K
+247.13%
Mar 24, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Value ETF
0%
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
佔比0%
Avantis US Small Cap Value ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Nov 05, 2020
Merger
4<1
Nov 05, 2020
Merger
4<1
Nov 05, 2020
Merger
4<1
Nov 05, 2020
Merger
4<1
公告日期
類型
比率
Nov 05, 2020
Merger
4<1
Nov 05, 2020
Merger
4<1
Nov 05, 2020
Merger
4<1
Nov 05, 2020
Merger
4<1
